Vahedi-Shahandashti Roya, Lass-Flörl Cornelia
Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria.
J Fungi (Basel). 2020 Oct 9;6(4):213. doi: 10.3390/jof6040213.
There is a need for new antifungal agents, mainly due to increased incidence of invasive fungal infections (IFI), high frequency of associated morbidity and mortality and limitations of the current antifungal agents (e.g., toxicity, drug-drug interactions, and resistance). The clinically available antifungals for IFI are restricted to four main classes: polyenes, flucytosine, triazoles, and echinocandins. Several antifungals are hampered by multiple resistance mechanisms being present in fungi. Consequently, novel antifungal agents with new targets and modified chemical structures are required to combat fungal infections. This review will describe novel antifungals, with a focus on the species.
由于侵袭性真菌感染（IFI）的发病率增加、相关发病率和死亡率较高以及当前抗真菌药物存在局限性（如毒性、药物相互作用和耐药性），因此需要新型抗真菌药物。临床上可用于治疗IFI的抗真菌药物主要限于四类：多烯类、氟胞嘧啶、三唑类和棘白菌素类。几种抗真菌药物受到真菌中存在的多种耐药机制的阻碍。因此，需要具有新靶点和修饰化学结构的新型抗真菌药物来对抗真菌感染。本综述将描述新型抗真菌药物，重点关注[此处原文species有误，可能是具体药物种类等，需确认准确信息后完善]。
